INmune Bio (NASDAQ: INMB)
INmune Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
INmune Bio Company Info
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
News & Analysis
INmune Bio (INMB) Q2 Loss Widens 110%
Why INmune Bio Stock Soared Then Sank Today
The wild ride for the biotech stock started with its announcement of results from a phase 1b study.
Valuation
Earnings Transcripts
INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript
INMB earnings call for the period ending June 30, 2022.
INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript
INMB earnings call for the period ending March 31, 2022.
INmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript
INMB earnings call for the period ending December 31, 2021.
INmune Bio, Inc. (INMB) Q3 2021 Earnings Call Transcript
INMB earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.